ScoreWhy is Anhui Anke Biotechnology (Group) Co., Ltd. ?
1
Poor long term growth as Net Sales has grown by an annual rate of 6.52% and Operating profit at 11.86% over the last 5 years
2
Flat results in Mar 26
- ROCE(HY) Lowest at 15.72%
- NET SALES(Q) Lowest at CNY 541.72 MM
- OPERATING PROFIT(Q) Lowest at CNY 188.32 MM
3
With ROE of 14.76%, it has a fair valuation with a 1.94 Price to Book Value
- Over the past year, while the stock has generated a return of -3.87%, its profits have fallen by -0%
- At the current price, the company has a high dividend yield of 3.1
4
Consistent Underperformance against the benchmark over the last 3 years
- Along with generating -3.87% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Anhui Anke Biotechnology (Group) Co., Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Anhui Anke Biotechnology (Group) Co., Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Anhui Anke Biotechnology (Group) Co., Ltd.
-6.21%
-0.33
39.34%
China Shanghai Composite
21.43%
1.55
13.83%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
6.52%
EBIT Growth (5y)
11.86%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.28
Sales to Capital Employed (avg)
0.64
Tax Ratio
10.50%
Dividend Payout Ratio
56.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
31.01%
ROE (avg)
18.43%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
13
Industry P/E
Price to Book Value
1.94
EV to EBIT
10.26
EV to EBITDA
9.09
EV to Capital Employed
2.43
EV to Sales
2.97
PEG Ratio
NA
Dividend Yield
3.14%
ROCE (Latest)
23.72%
ROE (Latest)
14.76%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
Bearish
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend4What is working for the Company
INTEREST COVERAGE RATIO(Q)
The company hardly has any interest cost
RAW MATERIAL COST(Y)
Fallen by -0.43% (YoY
CASH AND EQV(HY)
Highest at CNY 3,240.94 MM
-7What is not working for the Company
ROCE(HY)
Lowest at 15.72%
NET SALES(Q)
Lowest at CNY 541.72 MM
OPERATING PROFIT(Q)
Lowest at CNY 188.32 MM
Here's what is working for Anhui Anke Biotechnology (Group) Co., Ltd.
Cash and Eqv
Highest at CNY 3,240.94 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by -0.43% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Anhui Anke Biotechnology (Group) Co., Ltd.
Net Sales
At CNY 541.72 MM has Fallen at -18.12%
over average net sales of the previous four periods of CNY 661.63 MMMOJO Watch
Near term sales trend is extremely negative
Net Sales (CNY MM)
Net Sales
Lowest at CNY 541.72 MM
in the last five periodsMOJO Watch
Near term sales trend is negative
Net Sales (CNY MM)
Operating Profit
Lowest at CNY 188.32 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is negative
Operating Profit (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
